8 results match your criteria: "The Mount Sinai Icahn School of Medicine[Affiliation]"

The CORAL study highlighted the need to develop novel salvage regimens in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) previously treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. Carfilzomib (CFZ) can overcome rituximab chemotherapy resistance in lymphoma preclinical models by targeting the ubiquitin-proteasome system. We conducted an investigator initiated, single-center, open-label, prospective phase 1 study evaluating the safety and efficacy of CFZ in combination with rituximab, ifosfamide, carboplatin, and etoposide (C-R-ICE) in high-dose chemotherapy with autologous stem cell transplant (HDC-ASCT) eligible patients with R/R DLBCL (NCT01959698).

View Article and Find Full Text PDF

Chi Time: Expanding a novel approach for hospital employee engagement.

Nurs Manage

April 2020

At the Mount Sinai Icahn School of Medicine in New York, N.Y., Maggie Keogh is the director of the Chi Time program for the Center for Spirituality and Health, Deborah B. Marin is the Blumenthal professor of psychiatry and the director of the Center for Spirituality and Health, Lina Jandorf is a professor in the department of population health science and policy and the director of the Office of Community Engagement at the Tisch Cancer Institute, John B. Wetmore is a clinical research coordinator, and Vanshdeep Sharma is the medical director of the Center for Spirituality and Health.

View Article and Find Full Text PDF

Skin is an efficient protective barrier armed with an intricate network of antioxidants. External environmental stress diminishes and sometimes overwhelms these innate protective mechanisms; aging slows their efficacy. Topical antioxidants enhance natural endogenous defenses to create an indwelling reservoir for sustained protection with far higher concentrations than possible with oral intake.

View Article and Find Full Text PDF

Background: Elbow contracture is a sequelae of elbow trauma in pediatric patients. Arthroscopic contracture release has been shown to provide equivalent results to open contracture release with less associated morbidity and complications in the adult population. However, open contracture release is still commonly utilized in pediatric patients.

View Article and Find Full Text PDF

Recent research has given us new insights into the molecular biology of extrinsic aging of the skin. Not only does UV irradiation directly cause photoaging of the skin, but also environmental pollutants significantly damage exposed skin by several mechanisms. Exposure to the noxious gases of air pollution with simultaneous exposure to UVA can act synergistically to initiate skin cancer.

View Article and Find Full Text PDF

The Chi Cart ministry.

Nurs Manage

August 2017

At the Mount Sinai Icahn School of Medicine in New York, N.Y., Maggie Keogh is a Center for Spirituality and Health chaplain, Vanshdeep Sharma is the medical director of the Center for Spirituality and Health, and Deborah B. Marin is the Blumenthal professor of psychiatry and the director of the Departments of Spiritual Care and Education. Sandra L. Myerson is the president and CEO of SLM Consulting, LLC.

View Article and Find Full Text PDF

Body-Weight Fluctuations and Outcomes in Coronary Disease.

N Engl J Med

April 2017

From the New York University School of Medicine (S.B.), Pfizer (R.F., R.L., D.A.D.), and the Mount Sinai Icahn School of Medicine (F.H.M.) - all in New York; University Hospital, Bern, Switzerland (F.H.M.); Jagiellonian University, Krakow, Poland (F.H.M.); and San Francisco General Hospital, San Francisco (D.D.W.).

Background: Body-weight fluctuation is a risk factor for death and coronary events in patients without cardiovascular disease. It is not known whether variability in body weight affects outcomes in patients with coronary artery disease.

Methods: We determined intraindividual fluctuations in body weight from baseline weight and follow-up visits and performed a post hoc analysis of the Treating to New Targets trial, which involved assessment of the efficacy and safety of lowering low-density lipoprotein cholesterol levels with atorvastatin.

View Article and Find Full Text PDF